Summary
| Buyer: | The Procter & Gamble Company (PG) | Last Price: | 66.09 | Market Cap.: | 209.42B |
|---|---|---|---|---|---|
| Target: | Fomento Econo Mexicano, SAB de C.V (ADR) (FMX) | Last Price: | 118.91 | Market Cap.: | 70.91B |
Lines of Business Summary:
- The Procter & Gamble Company (PG) competes in 3 industries and 55 product/service groups
- Fomento Econo Mexicano, SAB de C.V (ADR) (FMX) competes in 2 industries and 6 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- The Procter & Gamble Company (PG) has 9 and Fomento Econo Mexicano, SAB de C.V (ADR) (FMX) has 0 suppliers that rely on a material % of their business. They share 0 in common.
- The Procter & Gamble Company (PG) has 1 and Fomento Econo Mexicano, SAB de C.V (ADR) (FMX) has 0 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
866 | |
Biopharmaceuticals |
|
326 | |
|
Medical Devices |
|
246 | |
|
Nutritional Health |
|
22 | |
|
Scientific Products |
|
40 | |
|
*Media |
|
146 | |
|
Entertainment/Programming |
|
38 | |
|
Manufacturing |
|
|
1,185 |
|
Consumer Manufacturing |
|
|
341 |
|
Materials |
|
447 | |
|
Retail and Wholesale |
|
288 | |
|
Food and Beverage |
|
31 |
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 74)
|
Target (Total: 31)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 56)
|
Target (Total: 1)
|
Buyer (Total: 11)
|
Target (Total: 2)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 138,000 | 93,342 |
| Revenue Per Employee | 545,988.6 | 130,684.9 |
| Total Revenue | 18,785.0 | 2,956.1 |
| Total Expenses | 14,731.0 | 2,546.7 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
8,865.0 | 1,611.0 |
|
SG&A Expense
|
5,866.0 | 0.0 |
|
Research & Development
|
0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 935.7 |
|
Operating Income
|
4,054.0 | 409.4 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
35.89 | 34.01 |
|
Fwd P/E
|
21.63 | 23.36 |
|
Fwd P/Rev
|
2.74 | 6.21 |
| Book Value | 62,373.0 | 4,895.4 |
|
Curr Portion of LTD/Cap Lease
|
1,986.0 | 305.5 |
Individual Company Summary
Focused
Buyer
Focused ():
Manufacturing > Consumer Manufacturing > Personal Care and Cleaning Products
Target
Focused ():
Manufacturing > Consumer Manufacturing > Food, Beverage and Agriculture > Beverages > Non-Alcoholic Beverages > Bottling/Distribution
Business Description
Buyer
The Procter & Gamble Company (P&G) is focused on providing branded consumer goods products. The Company is organized into three global business units: Beauty and Health; Household Care, and Gillette GBU. Its products are sold in over 180 countries around the world primarily through mass merchandisers, grocery stores, membership club stores and drug stores. The Company owns or has licenses under patents and registered trademarks, which are used in connection with its activity in all businesses. Some of these patents or licenses cover product formulation and processes used to manufacture its products. P&G created new categories with new brands, such as Febreze, Swiffer, Kandoo, Prilosec OTC and ThermaCare. In September 2006, the Company's Sure brand (an antiperspirant and deodorant brand) was acquired by Innovative Brands, LLC.
Target
Fomento Economico Mexicano S.A.B de C.V., formerly Fomento Economico Mexicano S.A. de C.V., is primarily a holding company engaged in the beverage business. Its principal operating subsidiaries include Coca-Cola FEMSA, S.A. de C.V. (Coca-Cola FEMSA), FEMSA Cerveza, S.A. de C.V. (FEMSA Cerveza) and FEMSA Comercio, S.A. de C.V. (FEMSA Comercio). Coca-Cola FEMSA is engaged in the production, distribution and marketing of certain Coca-Cola trademark beverages in Mexico, Guatemala, Nicaragua, Costa Rica, Panama, Colombia, Venezuela, Brazil and Argentina. FEMSA Cerveza produces, distributes and markets beer through its operating subsidiary, Cerveceria Cuauhtemoc Moctezuma, S.A. de C.V., which operates six breweries in Mexico, and produces and distributes 15 brands of beer, which include Tecate, Sol, Carta Blanca, Superior and Indio. FEMSA Comercio is engaged in the operation of a chain of convenience stores under the trade name Oxxo. Its other business segment consists of smaller operations.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
51.77 | 46.21 |
|
Operating Margin %
|
19.73 | 14.11 |
|
Quick Ratio
|
0.7 | 0.65 |
|
Current Ratio
|
1.24 | 0.92 |
|
Coverage Ratio
|
-0.09 | -0.13 |
| Total Assets | 137,048.0 | 13,009.8 |
| Return on Equity % | 14.66 | 17.3 |
| Return on Assets % | 6.82 | 6.51 |
|
Cash+ ST Inv. Per Share
|
2.27 | 8.34 |
| Total Debt | 37,713.0 | 3,540.9 |
| Total Debt to Equity % | 59.1 | 72.33 |
| Total Debt to Tangible Equity % | n/a | 72.33 |
|
Debt to Asset %
|
27.52 | 27.22 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Scientific Products |
|
|
|
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
|
|
|
|
*Media |
|
|
|
Entertainment/Programming |
|
|
|
Television
Companies involved in Production, Post Production, and Advertising production for the television industry.
|
|
|
|
Manufacturing |
|
|
|
Consumer Manufacturing |
|
|
|
Food, Beverage and Agriculture
Includes agricultural inputs like livestock and crops, as well as processed food and beverage products. Tobacco growers and cigarette manufacturers are also included.
|
|
|
|
Household Products
The Household Products sector includes furniture and other home and institutional decorative items, major and small appliances, kitchenware, and other related products.
|
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Materials |
|
|
|
Metal and Mineral Products
The Metal and Mineral Products Subsector includes companies that produce primary and industrial metal products, as well as clay, ceramic and glass products.
|
|
|
|
Retail and Wholesale |
|
|
|
Food and Beverage |
|
|
|
Grocery Stores
Grocery stores such as convenience stores and supermarkets.
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Upper Respiratory |
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Arrhythmia |
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Psoriasis |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, and causing the shedding of the horny layer of the skin by modulating cell differentiation and proliferation.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
Antisecretory Agents/Nitroimidazoles/Tetracyclines
Therapeutics that treat peptic ulcers by preventing the secretion of acid as well as treating infections by using antibiotics.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Diarrhea |
|
|
|
Antisecretory Agents
Therapeutics that treat diarrhea by bringing fluid movement within the intestine to normal levels.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, and causing the shedding of the horny layer of the skin by modulating cell differentiation and proliferation.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Heliobacter pylori |
|
|
|
Antisecretory Agents/Nitroimidazoles/Tetracyclines
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Heterotopic Ossification |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat ossification by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Osteoporosis |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Calcium Channel Inhibitors
Therapeutics that treat spasticity by preventing the release of calcium from the sarcoplasmic reticulum which results in reduced involuntary muscle contractions.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Female Genital Disorders |
|
|
|
Sexual Dysfunction |
|
|
|
Androgens
Therapeutics that treat female sexual dysfunction by providing male sex hormone, such as testosterone, that is important for the normal functioning of the female reproductive system.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Amphetamines
Therapeutics that treat coughs and colds by helping to relieve nasal congestion.
Buyer Products:
|
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antitussives/Expectorants
Therapeutics that treat coughs and colds by suppressing coughs and helping ejection of the mucous.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Buyer Products:
|
|
|
|
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing the cough, helping in the ejection of mucous and helping relieve fever and pain.
Buyer Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Buyer Products:
|
|
|
|
Expectorants/Opioids
Therapeutics that treat coughs and colds by suppressing the cough and helping in the ejection of the mucous.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Complications |
|
|
|
Hyperthermia |
|
|
|
Calcium Channel Inhibitors
Therapeutics that treat hyperthermia by preventing the release of calcium from the sarcoplasmic reticulum which results in inhibits the catabolic processes responsible for increase in temperature.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies |
|
|
|
Diagnostic |
|
|
|
Temperature |
|
|
|
Thermometers
Medical instruments designed to measure the temperature in patients
Buyer Products:
|
|
|
|
Orthopedics |
|
|
|
Treatment |
|
|
|
Pain Management |
|
|
|
General Purpose |
|
|
|
Dry Heat Therapy
Devices that control the of use dry heat to ease pain associated with musculoskeletal injuries.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Scientific Products |
|
|
|
Consumables |
|
|
|
Bioanalytical Chemistry |
|
|
|
Cell Biology |
|
|
|
Cell Proliferation |
|
|
|
Kits
Cell proliferation consumables that are a collection of reagents, standards, and other consumables assembled for used in various biological analyses.
Buyer Products:
|
|
|
|
*Media |
|
|
|
Entertainment/Programming |
|
|
|
Television |
|
|
|
Production |
|
|
|
Domestic |
|
|
|
Soap Opera
Shows depicting the interconnected lives of many characters often in a sentimental, melodramatic way.
Buyer Products:
|
|
|
|
Manufacturing |
|
|
|
Consumer Manufacturing |
|
|
|
Food, Beverage and Agriculture |
|
|
|
Beverages |
|
|
|
Alcoholic Beverages |
|
|
|
Breweries
Beer manufacturing. This also includes non-alcoholic beer manufacturing.
Target Products:
|
|
|
|
Non-Alcoholic Beverages |
|
|
|
Bottled Water
Bottled Water Manufacturing. Includes filtered water distribution services.
Target Products:
|
|
|
|
Bottling/Distribution
Companies which bottle, market, and distribute soft drinks and/or bottled water by license agreement with established manufacturers, like Coca Cola or Pepsi.
Target Products:
|
|
|
|
Coffee/Tea
Coffee and Tea Manufacturing.
Buyer Products:
|
|
|
|
Food |
|
|
|
Pet Food
Food for dogs and cats.
Buyer Products:
|
|
|
|
Sweets/Snacks |
|
|
|
Snack Foods
Manufacturers of Potato Chips, Peanuts, Trail Mix, and Cheese Snacks.
Buyer Products:
|
|
|
|
Household Products |
|
|
|
Household Appliances and Tools |
|
|
|
Other Household Products |
|
|
|
Brooms, Brushes, and Mops
Brooms, brushes, mops, and other manual cleaning equipment.
Buyer Products:
|
|
|
|
Small Electrical Appliances/Accessories |
|
|
|
Consumer Batteries
Relatively small, portable batteries used to power all varieties of consumer electronic devices. These one-time-use or rechargeable batteries store electric energy and can be used to power various devices ranging from CD players to cell phones. The most popular battery types include: lithium (Li), lithium ion (Li-ion), nickel-metal hybrid (NiMH), and nickel-cadmium (NiCAD). Flashlights are included at this level.
Buyer Products:
|
|
|
|
Kitchen/Bath Appliances
Electrical Kitchen/Bath Appliances, including toasters; juicemakers; and food blenders, as well as electrical toothbrushes, hairdryers, and electric massagers.
Buyer Products:
|
|
|
|
Personal Care and Cleaning Products |
|
|
|
Absorbent Products
Absorbent products, including tampons, pads, and diapers.
Buyer Products:
|
|
|
|
Anti-Perspirant
Anti-Perspirant and/or deodorant.
Buyer Products:
|
|
|
|
Cosmetics
Companies engaged in the manufacturing of cosmetics, such as lipstick, powders, and other make-up.
Buyer Products:
|
|
|
|
Fragrances
Companies engaged in the manufacturing of fragrances, such as perfume and cologne.
Buyer Products:
|
|
|
|
Hair Care
Companies engaged in the manufacturing of hair care products, such as shampoo, conditioner, hair dye, hair spray, styling gel, and mousse. Also includes hair accessories, such as pins, clips, and curlers.
Buyer Products:
|
|
|
|
Household Cleaning Products
Chemical-based household cleaning products, such as detergent and surface cleaner. Also includes automotive cleaning products.
Buyer Products:
|
|
|
|
Oral Care
Oral Care products, including Toothpaste, Mouthwash, and denture adhesive.
Buyer Products:
|
|
|
|
Sanitary/Personal Care Paper
Companies engaged in the manufacturing of sanitary/personal care paper such as napkins and tissues.
Buyer Products:
|
|
|
|
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.
Buyer Products:
|
|
|
|
Soap/Body Wash
Soap, Body Wash, and Shower Gel.
Buyer Products:
|
|
|
|
Materials |
|
|
|
Metal and Mineral Products |
|
|
|
Metal |
|
|
|
Industrial Metal Products |
|
|
|
Packaging |
|
|
|
Metal Cans and Closures
Includes aluminum and other metal beverage and food cans as well as other small metal containers and closures.
Target Products:
|
|
|
|
Nonmetallic Minerals |
|
|
|
Glass and Glass Products |
|
|
|
Glass Containers
Includes companies engaged in the manufacturing of glass containers.
Target Products:
|
|
|
|
Retail and Wholesale |
|
|
|
Food and Beverage |
|
|
|
Grocery Stores |
|
|
|
Convenience Stores
Convenience stores that sell a limited number of food and snack items.
Target Products:
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
GlaxoSmithKline plc (ADR)
|
|
n/a | 160,912.867 | 15.31 | 15.44 | 3.52 | 3.58 | 15.41 | |
|
Diageo plc (ADR)
|
|
n/a | 54,022.767 | 19.29 | 17.49 | 2.84 | 2.83 | n/a | |
|
Unilever N.V. (ADR)
|
|
n/a | 46,726.337 | 10.64 | 16.91 | 0.90 | n/a | n/a | |
|
Bayer AG (ADR)
|
|
n/a | 43,437.441 | 23.33 | 16.59 | 1.13 | 1.15 | n/a | |
|
Unilever plc (ADR)
|
|
n/a | 36,645.065 | 8.21 | 17.17 | 0.70 | 0.73 | n/a | |
|
Cadbury Schweppes plc (ADR)
|
|
n/a | 23,090.721 | 21.09 | 18.71 | 1.90 | 1.90 | n/a | |
|
Gucci Group N.V. (ADR)
|
|
n/a | 10,616.224 | 49.60 | n/a | 3.34 | n/a | 6.46 | |
|
The Estee Lauder Companies Inc.
|
|
n/a | 8,546.892 | 35.03 | 19.39 | 1.30 | 1.23 | 10.35 | |
|
Energizer Holdings, Inc.
|
|
n/a | 4,346.690 | 16.66 | 16.47 | 1.41 | 1.35 | n/a | |
|
Church & Dwight Co., Inc.
|
|
n/a | 2,910.079 | 22.17 | 22.01 | 1.57 | 1.50 | 19.85 | |
|
Del Monte Foods Company
|
|
n/a | 2,287.919 | 16.44 | 15.07 | 0.72 | 0.65 | n/a | |
|
Kyphon Inc.
|
|
n/a | 1,976.269 | 63.28 | 51.38 | 5.19 | 4.92 | 6.46 | |
|
Adams Respiratory Therapeutics, Inc.
|
|
n/a | 1,601.618 | 31.94 | 23.61 | 5.67 | 4.15 | 13.66 | |
|
Chattem Inc.
|
|
n/a | 1,077.971 | 25.29 | 30.19 | 3.60 | 3.49 | n/a | |
|
Axcan Pharma Inc. (USA)
|
|
n/a | 698.123 | 17.85 | 16.00 | 2.39 | 2.33 | 10.86 | |
|
Helen of Troy Limited
|
|
n/a | 698.074 | 14.85 | 14.95 | 1.12 | 1.11 | 6.08 | |
|
Spectrum Brands, Inc.
|
|
n/a | 620.243 | n/a | 17.91 | 0.24 | 0.24 | n/a | |
|
GTx, Inc.
|
|
n/a | 618.142 | n/a | -12.82 | 174.12 | 126.25 | 15.81 | |
|
Salix Pharmaceuticals Ltd
|
|
n/a | 595.549 | 40.49 | 20.09 | 3.03 | 2.95 | 3.47 | |
|
Impax Laboratories Inc.
|
|
n/a | 578.999 | 495.64 | 27.46 | 5.14 | n/a | 9.87 | |
|
Revlon, Inc.
|
|
n/a | 515.876 | n/a | -2.40 | 0.37 | 0.37 | n/a | |
|
Green Mountain Coffee Roasters Inc.
|
|
n/a | 417.684 | 49.47 | 35.60 | 1.85 | 1.37 | n/a | |
|
Inter Parfums, Inc.
|
|
n/a | 391.406 | 24.24 | 22.40 | 1.32 | 1.23 | 4.59 | |
|
Santarus, Inc.
|
|
n/a | 359.469 | n/a | -5.36 | 10.43 | 7.65 | 8.86 | |
|
Peet's Coffee & Tea, Inc.
|
|
n/a | 339.973 | 38.09 | 39.59 | 1.69 | 1.59 | 2.94 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Alexion Pharmaceuticals, Inc.
|
|
99.50% | 1,486.169 | n/a | -10.35 | 730.20 | 904.78 | n/a | |
|
Multi-Color Corp.
|
|
30.00% | 226.879 | 20.10 | 19.47 | 1.05 | n/a | 5.08 | |
|
Tredegar Corporation
|
|
25.00% | 860.305 | 30.68 | 23.47 | 0.79 | n/a | 2.29 | |
|
Buckeye Technologies Inc.
|
|
13.00% | 462.875 | 76.18 | 23.61 | 0.61 | 0.57 | 3.22 | |
|
Valassis Communications, Inc.
|
|
10.00% | 655.428 | 10.13 | 8.71 | 0.61 | 0.63 | 28.07 | |
|
Regeneron Pharmaceuticals, Inc.
|
|
9.00% | 1,250.706 | n/a | -12.09 | 17.73 | 18.38 | 20.02 | |
|
CTC Media, Inc.
|
|
4.60% | 3,230.102 | 49.17 | 31.26 | 9.41 | 8.78 | 13.14 | |
|
Curis, Inc.
|
|
2.00% | 64.005 | n/a | n/a | 5.17 | 6.17 | 2.55 | |
|
Noven Pharmaceuticals, Inc.
|
|
0.20% | 634.852 | 42.52 | 43.27 | 10.54 | 10.49 | 3.97 | |
|
American Express Company
|
|
n/a | 69,985.321 | 19.83 | 19.60 | 2.65 | 2.64 | 6.51 | |
|
WPP Group plc (ADR)
|
|
n/a | 18,051.611 | 23.49 | 19.78 | 1.65 | 1.60 | n/a | |
|
Boston Properties, Inc.
|
|
n/a | 14,010.703 | 14.67 | 26.81 | 9.56 | 9.86 | 3.67 | |
|
Publicis Groupe S.A. (ADR)
|
|
n/a | 7,671.863 | 13.39 | 17.30 | 1.40 | 1.37 | n/a | |
|
Metso Oyj (ADR)
|
|
n/a | 7,010.319 | 15.11 | 16.46 | 1.15 | n/a | 7.11 | |
|
BEA Systems, Inc.
|
|
n/a | 4,880.428 | 33.87 | 31.46 | 3.77 | 3.44 | 4.77 | |
|
Huntsman Corporation
|
|
n/a | 4,610.805 | 24.58 | 12.87 | 0.41 | 0.37 | 2.83 | |
|
Focus Media Holding Limited (ADR)
|
|
n/a | 4,071.087 | 65.10 | 44.23 | 24.03 | 18.59 | 16.69 | |
|
Beckman Coulter, Inc.
|
|
n/a | 3,968.324 | 27.87 | 21.81 | 1.61 | 1.52 | 10.79 | |
|
Crown Holdings, Inc.
|
|
n/a | 3,585.316 | n/a | 18.91 | 0.51 | 0.51 | n/a | |
|
Owens-Illinois, Inc.
|
|
n/a | 3,413.335 | n/a | 26.59 | 0.46 | 0.45 | n/a | |
|
Central European Media Enterprises Ltd.
|
|
n/a | 3,382.617 | 117.49 | 97.56 | 6.25 | 5.72 | n/a | |
|
Meredith Corporation
|
|
n/a | 2,714.317 | 18.23 | 17.41 | 1.69 | 1.68 | 15.37 | |
|
Fair Isaac Corporation
|
|
n/a | 2,361.232 | 22.82 | 19.98 | 2.86 | 2.72 | n/a | |
|
Silgan Holdings Inc.
|
|
n/a | 1,756.912 | 18.07 | 17.33 | 0.67 | 0.65 | 249.95 | |
| Target | |||||||||
|
Coca-Cola Femsa SAB de CV
|
|
n/a | 7,304.872 | 15.87 | 16.08 | 1.45 | 1.37 | 2.11 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Wal-Mart Stores, Inc.
|
|
15.00% | 201,357.296 | 18.42 | 16.92 | 0.59 | 0.58 | 4.42 | |
|
sanofi-aventis (ADR)
|
|
n/a | 124,749.857 | 32.87 | 14.47 | 3.34 | 3.48 | n/a | |
|
Dollar General Corp.
|
|
n/a | 5,451.218 | 23.38 | 21.37 | 0.60 | 0.60 | 3.20 | |
|
Tween Brands Inc.
|
|
n/a | 1,117.933 | 17.56 | 18.72 | 1.32 | 1.33 | 3.28 | |
|
99 Cents Only Stores
|
|
n/a | 1,026.895 | 65.74 | 91.25 | 1.03 | 0.92 | 2.07 | |
|
Prestige Brands Holdings, Inc.
|
|
n/a | 637.597 | 21.24 | 16.22 | 1.99 | 1.88 | n/a | |
|
Fred's, Inc.
|
|
n/a | 531.828 | 19.59 | 18.23 | 0.32 | 0.29 | 1.49 | |
|
United-Guardian, Inc.
|
|
n/a | 42.799 | 18.14 | n/a | 3.76 | n/a | 3.05 | |
|
AMCON Distributing Co.
|
|
n/a | 10.362 | n/a | n/a | 0.01 | n/a | n/a | |
|
Synergy Brands Inc.
|
|
n/a | 4.505 | n/a | n/a | 0.07 | n/a | 0.79 | |
|
Sally Beauty Holdings, Inc.
|
|
n/a | n/a | n/a | 23.27 | n/a | n/a | n/a | |
| Target | |||||||||
|
Coca-Cola Femsa SAB de CV
|
|
n/a | 7,304.872 | 15.87 | 16.08 | 1.45 | 1.37 | 2.11 | |
|
Molson Coors Brewing Company
|
|
n/a | 6,786.076 | 23.88 | 19.65 | 1.19 | 1.16 | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Berkshire Hathaway Inc.
|
|
n/a | 168,814.592 | 13.44 | n/a | 1.73 | n/a | 2.41 | |
|
sanofi-aventis (ADR)
|
|
n/a | 124,749.857 | 32.87 | 14.47 | 3.34 | 3.48 | n/a | |
|
Koninklijke Philips Electronics NV (ADR)
|
|
n/a | 43,895.890 | 6.97 | 32.99 | 1.24 | 1.29 | 1.85 | |
|
The Clorox Company
|
|
n/a | 9,780.018 | 21.88 | 19.93 | 2.08 | 2.00 | n/a | |
|
Dollar General Corp.
|
|
n/a | 5,451.218 | 23.38 | 21.37 | 0.60 | 0.60 | 3.20 | |
|
Wesco Financial Corporation
|
|
n/a | 3,353.431 | 10.83 | n/a | 3.59 | n/a | 1.61 | |
|
DreamWorks Animation SKG, Inc.
|
|
n/a | 3,064.783 | 30.74 | 53.57 | 8.43 | 9.17 | 3.02 | |
|
Invitrogen Corporation
|
|
n/a | 2,855.569 | n/a | 20.27 | 2.27 | 2.30 | n/a | |
|
Regis Corporation
|
|
n/a | 1,817.192 | 16.44 | 18.31 | 0.73 | 0.68 | n/a | |
|
Inverness Medical Innovations, Inc.
|
|
n/a | 1,490.884 | n/a | 74.04 | 2.79 | 2.71 | 75.40 | |
|
Alexion Pharmaceuticals, Inc.
|
|
n/a | 1,486.169 | n/a | -10.35 | 730.20 | 904.78 | n/a | |
|
Arbitron Inc.
|
|
n/a | 1,364.941 | 23.98 | 27.30 | 4.20 | 4.10 | 45.86 | |
|
Macrovision Corporation
|
|
n/a | 1,303.787 | 62.28 | 29.49 | 5.56 | 5.34 | 4.98 | |
|
Regeneron Pharmaceuticals, Inc.
|
|
n/a | 1,250.706 | n/a | -12.09 | 17.73 | 18.38 | 20.02 | |
|
Tween Brands Inc.
|
|
n/a | 1,117.933 | 17.56 | 18.72 | 1.32 | 1.33 | 3.28 | |
|
99 Cents Only Stores
|
|
n/a | 1,026.895 | 65.74 | 91.25 | 1.03 | 0.92 | 2.07 | |
|
Palomar Medical Technologies, Inc.
|
|
n/a | 921.978 | 24.71 | 28.07 | 8.48 | 8.07 | 10.21 | |
|
Helen of Troy Limited
|
|
n/a | 698.074 | 14.85 | 14.95 | 1.12 | 1.11 | 6.08 | |
|
Prestige Brands Holdings, Inc.
|
|
n/a | 637.597 | 21.24 | 16.22 | 1.99 | 1.88 | n/a | |
|
Noven Pharmaceuticals, Inc.
|
|
n/a | 634.852 | 42.52 | 43.27 | 10.54 | 10.49 | 3.97 | |
|
Fred's, Inc.
|
|
n/a | 531.828 | 19.59 | 18.23 | 0.32 | 0.29 | 1.49 | |
| Target | |||||||||
|
Coca-Cola Femsa SAB de CV
|
|
n/a | 7,304.872 | 15.87 | 16.08 | 1.45 | 1.37 | 2.11 | |
|
Molson Coors Brewing Company
|
|
n/a | 6,786.076 | 23.88 | 19.65 | 1.19 | 1.16 | n/a | |
|
Heineken N.V. (ADR)
|
|
n/a | 6,182.142 | 5.72 | 20.36 | 0.43 | n/a | 2.61 | |
|
Sapporo Breweries Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 72,214.0 | 11,026.1 | 83,240.1 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 72,214.0 | 11,026.1 | 83,240.1 |
|
Cost of Revenue
|
34,831.0 | 5,930.8 | 40,761.8 |
|
SG&A Expense
|
23,137.0 | 0.0 | 23,137.0 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 3,539.2 | 3,539.2 |
| Total Expenses | 57,968.0 | 9,470.0 | 67,438.0 |
|
Operating Income
|
14,246.0 | 1,556.1 | 15,802.1 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-1,258.0 | -199.5 | -1,457.5 |
|
Other, Net
|
389.0 | -83.9 | 305.1 |
| Income Before Taxes | 13,377.0 | 1,272.8 | 14,649.8 |
| Income Taxes | 4,024.0 | 425.7 | 4,449.7 |
| Income After Taxes | 9,353.0 | 847.1 | 10,200.1 |
| Minority Interest (IS) | 0.0 | -243.1 | -243.1 |
|
Net Income - Excl. Xord. Items
|
9,353.0 | 604.0 | 9,957.0 |
|
Net Income - Incl. Xord. Items
|
9,353.0 | 604.0 | 9,957.0 |
| Preferred Dividends | -151.0 | 0.0 | -151.0 |
|
Income Avail. to Common
|
9,202.0 | 604.0 | 9,806.0 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
3,175.2 | 119.3 | 3,294.5 |
|
Basic EPS - Excl. Xord. Items
|
2.90 | 5.06 | 3.02 |
|
Basic EPS - Incl. Xord. Items
|
2.90 | 5.06 | 3.02 |
| Full Dilution Adjustment | 39.0 | 0.0 | 39.0 |
| Fully Diluted Shares Outstanding | 3,413.3 | 119.3 | 3,532.6 |
|
F.D. EPS - Excl. Xord. Items
|
2.70 | 5.06 | 2.82 |
|
F.D. EPS - Incl. Xord. Items
|
2.70 | 5.06 | 2.82 |
| Dividends Per Common Share | 1.18 | 2.92 | 4.10 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
6,718.0 | 994.9 | 7,712.9 |
|
ST Investments
|
1,040.0 | 0.0 | 1,040.0 |
|
Accounts Receivable
|
6,640.0 | 708.3 | 7,348.3 |
|
Inventory
|
6,790.0 | 655.8 | 7,445.8 |
|
Prepayments and Advances
|
2,752.0 | 0.0 | 2,752.0 |
|
Other Current Assets
|
1,565.0 | 29.1 | 1,594.1 |
|
Current Assets
|
25,505.0 | 2,388.1 | 27,893.1 |
|
PPE
|
32,474.0 | 0.0 | 32,474.0 |
|
Accum D&A
|
-13,736.0 | 0.0 | -13,736.0 |
|
PPE, Net
|
18,738.0 | 4,644.3 | 23,382.3 |
| Goodwill & Intangibles | 89,291.0 | 0.0 | 89,291.0 |
| Long Term Investments | 0.0 | 35.4 | 35.4 |
|
Note Receivable
|
0.0 | 73.3 | 73.3 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
3,514.0 | 5,868.7 | 9,382.7 |
| Total Assets | 137,048.0 | 13,009.8 | 150,057.8 |
| Liabilities | |||
| Accounts Payable | 4,507.0 | 841.2 | 5,348.2 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 9,943.0 | 0.0 | 9,943.0 |
|
ST Debt
|
0.0 | 711.9 | 711.9 |
|
Curr Port of LTD & Cap Lease Oblg
|
1,986.0 | 305.5 | 2,291.5 |
| Other (Current) Liabilities | 4,154.0 | 743.3 | 4,897.3 |
|
Current Liab.
|
20,590.0 | 2,601.9 | 23,191.9 |
|
LT Debt
|
35,727.0 | 2,523.5 | 38,250.5 |
|
Total LT Debt
|
35,727.0 | 2,523.5 | 38,250.5 |
| Minority Interest (BS) | 0.0 | 2,015.4 | 2,015.4 |
| Deferred Taxes | 12,429.0 | 314.4 | 12,743.4 |
|
Other LT Liab.
|
4,490.0 | 659.2 | 5,149.2 |
|
Total Liabilities
|
73,236.0 | 8,114.3 | 81,350.3 |
| Shareholders Equity | |||
| Redeemable Preferred | 1,440.0 | 0.0 | 1,440.0 |
| Common Stock | 3,981.0 | 0.0 | 3,981.0 |
| Additional Paid in Capital | 58,285.0 | 0.0 | 58,285.0 |
| Retained Earnings | 37,284.0 | 0.0 | 37,284.0 |
| Treasure Stock | -35,329.0 | 0.0 | -35,329.0 |
| Other Equity | -553.0 | 4,895.4 | 4,342.4 |
| ESOP Debt Guarantee | -1,295.0 | 0.0 | -1,295.0 |
|
Total Equity
|
63,813.0 | 4,895.4 | 68,708.4 |
|
Total Liab. & Equity
|
137,049.0 | 13,009.7 | 150,058.7 |
|
Shares Outstanding
|
3,168.8 | 119.3 | 3,288.0 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 9,353.0 | 677.9 | 10,030.9 |
| CF Depreciation | 2,963.0 | 473.6 | 3,436.6 |
| CF Deferred Taxes | -240.0 | 0.0 | -240.0 |
| Other Non-Cash Items | 674.0 | 42.5 | 716.5 |
| Change in Working Capital | -593.0 | -18.8 | -611.8 |
| Total Cash From Operating Activities | 12,157.0 | 1,175.2 | 13,332.2 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -2,836.0 | -379.4 | -3,215.4 |
| Other Investing Cash Flows | 3,228.0 | -291.5 | 2,936.5 |
| Total Cash From Investing Activities | 392.0 | -670.8 | -278.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -3,999.0 | 0.3 | -3,998.7 |
| Purchase Or Sale of Stock | -11,035.0 | -0.8 | -11,035.8 |
| Purchase and Retirement of Debt | 2,562.0 | -1,257.8 | 1,304.2 |
| Other Financing Cash Flow | 0.0 | 698.4 | 698.4 |
| Total Cash From Financing Activities | -12,472.0 | -292.2 | -12,764.2 |
| Exchange Rate Effects | 331.0 | 0.0 | 331.0 |
| Net Change in Cash | 408.0 | 212.2 | 620.2 |
| Cash Taxes Paid | 2,869.0 | 0.0 | 2,869.0 |
| Cash Interest Paid | 1,045.0 | 0.0 | 1,045.0 |